# TCRCure Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tcrcure-biopharma

- Industry: Biotechnology
- Headquarters: Chongqing, China
- Website: www.tcrcure.com
- Total disclosed funding: $47M
- Latest round: Series B (Feb 16, 2022)
- Investors on record: 9

## About

Established in 2016 and based in Chongqing, China, TCRCure Biopharma Ltd. operates as a tumor immune cell therapy technology developer that focuses on provides immunodiagnosis and precision medicine solution. The company has more than 150 employees and more than 40% members of its total employees have master's degree. The company cooperates with many hospitals such as Sun Yat-sen Medical University Cancer Hospital, Xinqiao Hospital, West China Hospital. The company developed TCR screening platform (TRUST) in May 2017. The company passed the GMP audit in November 2020. The company initated TC-E202 registration phase I study in December 2021.

The company provides immunodiagnosis and precision medicine solution for many patients with lung cancer, liver cancer and cervical cancer. The company's products include CAR-T, TCR-T, CAR-NK and TIL immune cell therapy products. The company's technology platform includes TRUST platform, CHECK-T cell engineering platform and TURBO-T cell engineering platform.

The company will invest in immune cell products R&D, expanding product line and constructing team.

## Funding rounds

- Series B, Feb 16, 2022, $47M — Detong Capital, Energy Transfer LP, Share Capital, CCB Trust Co., Ltd., Astra Zeneca CICC Healthcare Venture Capital Fund
- Series A, Apr 2, 2019 — Share Capital, In Capital, Beijing Zhihe Kangdao Biotechnology
- Series A, Nov 28, 2018 — Fang Fund Partners, Jiadaogu Capital

## Investors

- Fang Fund Partners (https://capitalatlas.ai/funds/fang-fund-partners) — Series A
- Jiadaogu Capital (https://capitalatlas.ai/funds/jiadaogu-capital) — Series A
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series A, Series B
- In Capital — Series A
- Beijing Zhihe Kangdao Biotechnology — Series A
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series B
- Energy Transfer LP — Series B
- CCB Trust Co., Ltd. — Series B
- Astra Zeneca CICC Healthcare Venture Capital Fund — Series B